Peptides for activation and inhibition of.delta.pkc
CA 2434643 C · Owner: The Board Of Trustees Of The Leland Stanford Junior University · Inventors: Chen, Leon; Mochly-Rosen, Daria
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Peptides able to inhibit or activate the translocation or function of öPKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described as , well as methods for screening test compounds for öPKC-selective agonists and antagonists.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 9, 2001 and granted October 29, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 9, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 9, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.